Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 12/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 10/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8510380 | 0.84 | CA2 (0.50) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL968880 | 0.84 | HTR1A (0.51) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL1568022 | 0.83 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL3641960 | 0.83 | CYP1A2 (0.51) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL6918962 | 0.83 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL7628613 | 0.81 | SIGMAR1 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL12064816 | 0.81 | CYP1A2 (0.54) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8935393 | 0.80 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL10645332 | 0.80 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8935402 | 0.80 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875607-B2 | Neurodegenerative disorders; antiinflammatory agents; antiischemic agents; neuropathic pain; antiepileptic agents; Parkinson's disease; Alzheimer's disease; antidiabetic agents; 3-(6-Hydroxy-2-methyl-3,4,7,8,9,10-hexahydro-7,10-methano-2H -benzo[h]chromen-2-yl)-propionic acid methyl ester | AMPERE LIFE SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090170814-A1 | 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES | EDISON PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7470798-B2 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | EDISON PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| WO-2005033093-A1 | 7,8-BICYCLOALKYL-CHROMAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050065149-A1 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | PTC THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065149-A1 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | NLN, ACAA2, CS | CA2 1309/4885HTR1A 833/4885SIGMAR1 1014/4885 |
| US-20090170814-A1 | 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES | COQ8A, TFAM, CS | CA2 2328/4885HTR1A 765/4885SIGMAR1 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.